Stay updated with breaking news from Cellular Oncogenesis Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Using advanced computing technology scientists at the Wistar Institute (Philadelphia) have been able to provide evidence of novel, reliable biomarkers that better predict therapy response of patients undergoing immune checkpoint inhibitor (ICI) treatment. Click to read more...
Researchers have identified key markers to help physicians predict whether or not a patient may respond positively to ...
Immune checkpoint inhibitor (ICI) therapy is a type of treatment for melanoma, the deadliest form of skin cancer, which blocks proteins on tumor or immune cells that prevent the immune system from killing cancer cells.
A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited to improve treatment of the aggressive childhood cancer, which accounts for roughly 15% of all deaths from pediatric malignancies.
FEBRUARY 7, 2021, NEW YORK – A Ludwig Cancer Research study has identified a potential vulnerability in neuroblastoma tumors that might be exploited